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ADEQUATE DISCLOSURES IN 140 CHARACTERS OR LESS—
ANALYSIS OF HOW ENDORSERS SHOULD APPROACH 





Social media websites such as Twitter and Facebook have transformed the 
way businesses and individuals market their products and services. These 
websites have given advertisers and promoters the ability to advertise directly 
to consumers who would most likely be interested in their products or services. 
In theory, this should benefit both the consumer and the owner of the product 
or provider of the service. The product owner or service provider can more 
efficiently use its marketing resources, and consumers will be exposed to 
advertisements of products and services catered to their interests. This 
increased ability to target specific consumers, however, brings an increased 
risk of consumer deception. After recognizing this increased risk, several 
federal agencies empowered to protect the consumer from deceptive trade 
practices have published guidance on how to proceed to communicate an 
advertisement on social media sites to avoid the risk of deception. This 
seemingly premature application of consumer law to these websites has created 
many problems and concerns. Many of these sites have character space 
limitations, “CLP’s”, which would restrict the ability of businesses to 
effectively communicate an advertisement while also providing the necessary 
disclosure requirements. While it is clear that these agencies are not excluding 
these mediums from disclosure requirements, which is where the clarity ends. 
This Article is focused on highlighting the major issues that arise for 
advertisers, consumers and promoters that are using social media sites. It also 
addresses common themes in each of the agencies’ guides concerning the use 
 
  Jacob Hughey, JD, is a practicing attorney in Richardson, TX. During law school Jacob took a Social 
Media and the Law course taught by John Browning, a veteran litigator, published author and one of the 
leading national authorities on social media’s presence in the legal profession. During this course, Jacob was 
consumed with how little has been done to combat consumer deception and privacy issues that are direct 
results from the ever-expanding world of social media. Outside of work, Jacob researches and writes articles in 
an effort to expose problems created by social media. 
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of social media websites and makes an effort to interpret a very unclear area of 
law. 
INTRODUCTION 
“If there is one thing more dishonest than dodgy marketing, it is the pretense 
that marketing raises no ethical concerns. The truth is that marketing raises 
enormous ethical questions every day—at least it does if you are doing it 
right.” 
—Rory Sutherland, Vice-Chairman, Ogilvy Group UK.
1
 
Rather than communicate this message through Twitter, Rory made this 
statement in an article posted on a marketing blog site. Which makes sense, 
because if Rory attempted to convey this message through Twitter it would 
look like this: 
“If there is one thing more dishonest than dodgy marketing, it is the pretense 
that marketing raises no ethical concerns. The truth is that” 
Like many social media sites, Twitter has character limitation requirements 
imposed on messages conveyed through its website. In order for Rory to 
effectively communicate his message he would have to create two separate 
tweets, shorten the length of his message, or provide a hyperlink that directs 
his followers to his full quotation on a separate website. So while Rory might 
be annoyed, he has different options to choose from as to how he would like to 
convey his message. 
Suppose that rather than posting a favorite quote on Twitter, Rory wanted 
to express how satisfied he is with his new blood pressure medication called 
“HEARTLY.” So with little premeditation, Rory promptly pulls out his mobile 
phone and publishes the following tweet: 
“Luv my new BP med. Feeling like a million bucks. #blessed #HEARTLY” 
While this is a clear endorsement of the drug HEARTLY, Rory is not under 
contract to promote HEARTLY, and his Twitter followers would not be misled 
if they assumed that this was Rory’s truthful opinion and experience with the 
drug. 
 
 1 Rory Sutherland, We Can’t Run Away from the Ethical Debates in Marketing, MARKETING SOCIETY: 
THE LIBRARY (July 9, 2012), https://www.marketingsociety.com/the-library/we-cant-run-away-ethical-
debates-marketing.  
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Let’s change the facts again. Let’s assume that Rory is not a person but 
actually an advertiser of the drug HEARTLY. Now if Rory makes the same 
statement about the drug HEARTLY, Rory’s statement is transformed from an 
opinion into an advertisement subject to FDA regulations. These regulations 
would require an advertisement of a blood pressure medication such as 
HEARTLY to contain certain disclosures about the risks of using HEARTLY. 
The FDA has made it clear that advertisements conveyed through platforms 
such as Twitter are not exempt from these disclosures. Accordingly, any 
message without these disclosures would subject Rory and other parties 
involved with the drug HEARTLY to liability. 
Once more we change the facts and assume Rory is a male celebrity who 
uses HEARTLY and sincerely enjoys the benefits that he has experienced 
using HEARTLY. Rory also has an endorsement deal with HEARTLY and 
makes a commission based on the amount of HEARTLY sold each month. 
Rory wants to publish the following message on his Twitter: 
“Luv HEARTLY- BEST BP drug ever” 
This poses a problem for Rory as well as the marketing team of 
HEARTLY. This tweet would be considered an endorsement of a product by 
an individual with a material connection between himself and the drug. While 
this tweet is Rory’s honest and truthful opinion about HEARTLY, the fact that 
Rory is benefiting from the sale of the drug must be disclosed to prevent 
consumer deception. Despite there being no evidence of Rory’s intent to 
mislead his followers, the federal agencies created to protect consumers are not 
concerned with the subjective intent of the endorser. Their focus is on how the 
consumer perceives the message.
2
 This poses the question of how much 
disclosure is necessary to prevent liability. Would it be sufficient to just 
disclose the material connection that the celebrity has in the message with an 
#Ad or similar abbreviation? Or is the celebrity also required to comply with 
the disclosure requirements provided by the FDA regarding the prescription 
drug HEARTLY in 140 characters or less? 
The answer is unclear. In an effort to comply with disclosure requirements 
while marketing on these Character Limited Platforms (“CLP’s”), many 
 
 2 See FTC Guides Concerning the Use of Endorsements and Testimonials in Advertising, 74 Fed. Reg. 
53,124, 53,125 (Oct. 15, 2009) (to be codified at 16 C.F.R. pt. 255) (“The guides of the FTC have always 
defined ‘endorsements’ by focusing on the message consumers take from the speech at issue.”) [hereinafter 
Advertising Guides]. 
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businesses and individuals have asked for guidance from consumer protection 
agencies on how they should approach advertising on CLP’s like Twitter.
3
 In 
response to their pleadings, these agencies have published and edited previous 
guidance documents that attempt to address how advertisers should approach 
marketing on CLP’s.
4
 While each agency was created with a different purpose, 
many of their responsibilities with regard to consumer protection overlap. The 
published guides have similar messages and themes. For example, they each 
make it clear that CLP’s are not exempt from disclosure requirements.
5
 Many 
times a simple #AD or hyperlink is not sufficient disclosure, and if the required 
disclosure in the message does not fit the CLP’s space requirements, the 
advertisement should not be published on that platform.
6
 
I. THE RISE OF SOCIAL MEDIA AND ITS EFFECT ON MARKETING 
A. Definition of Social Media 
There have been many definitions of social media and what it entails. So 
for the purpose of this Article, it will be defined broadly as provided by the 
FFIEC: 
 
 3 See U.S. FOOD AND DRUG ADMIN., FOR INDUSTRY: USING SOCIAL MEDIA, http://www.fda.gov/ 
AboutFDA/CentersOffices /OfficeofMedicalProductsandTobacco/CDER/ucm397791.htm (last updated Oct. 
29, 2014) (FDA gathering input necessary to “provide guidance on the promotion of FDA-regulated medical 
products using the Internet and social media tools.”); Social Media: Consumer Compliance Risk Management 
Guidance, 78 Fed. Reg. 4,848-01 (Jan. 23, 2013) (inviting comments on the “application of consumer 
protection laws and regulations within the realm of social media.”). See, e.g., Pradnya Joshi, Approval by a 
Blogger May Please a Sponsor, N.Y. TIMES (July 12, 2009), http://www.nytimes.com/2009/07/13/technology/ 
internet/13blog.html (discussing the increasing prevalence of online endorsements and the blurred line 
between personal opinion and advertising). 
 4 See FED. TRADE COMM’N, FTC STAFF REVISES ONLINE ADVERTISING DISCLOSURE GUIDELINES, 
(Mar. 12, 2013), https://www.ftc.gov/news-events/press-releases/2013/03/ftc-staff-revises-online-advertising-
disclosure-guidelines; Thomas Abrams, FDA Issues Draft Guidances for Industry on Social Media and 
Internet Communications About Medical Products: Designed with Patients in Mind, U.S. FOOD AND DRUG 
ADMIN.: FDA VOICE (June 17, 2014), http://blogs.fda.gov/fdavoice/index.php/2014/06/fda-issues-draft-
guidances-for-industry-on-social-media-and-internet-communications-about-medical-products-designed-with-
patients-in-mind/; FED. FIN. INST. EXAMINATION COUNCIL, FINANCIAL REGULATORS ISSUE FINAL GUIDANCE 
ON SOCIAL MEDIA, (Dec. 11, 2013), https://www.ffiec.gov/press/pr121113.htm.  
 5 Compare U.S. FOOD & DRUG ASS’N, GUIDANCE FOR INDUSTRY: INTERNET/SOCIAL MEDIA PLATFORMS 
WITH CHARACTER SPACE LIMITATIONS, at 5 (June 18, 2014), http://www.fda.gov/downloads/drugs/ 
guidancecomplianceregulatoryinformation/guidances/ucm401087.pdf [hereinafter FDA Guides], with FED. 
FIN. INST. EXAMINATION COUNCIL, SOCIAL MEDIA: CONSUMER COMPLIANCE RISK MANAGEMENT GUIDANCE, 
at 8 (Dec. 11, 2003) https://www.ffiec.gov/press/PDF/2013_Dec%20Final%20SMG%20attached%20to%2011 
Dec13%20press%20release.pdf.  
 6 See FED. TRADE COMM’N, supra note 4; FDA Guides, supra note 5 at 5. 
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Social media is considered to be a form of interactive online 
communication in which users can generate and share content 
through text, images, audio, and/or video. Social media can 
take many forms, including, but not limited to, micro-
blogging sites (e.g. Facebook, Google Plus, MySpace, and 
Twitter); Forums, blogs, customer review websites and 
bulletin boards (e.g. Yelp); photo and video sites (e.g., Flickr 
and YouTube); sites that enable professional networking 
(e.g., LinkedIn); virtual worlds (e.g., Second Life); and social 
games (e.g., FarmVille and CityVille).
7
 
The FFIEC states that, “social media can be distinguished from other 
online media in that communication tends to be more interactive.”
8
 It is this 
interaction between businesses and consumers that generates concerns in the 
world of advertising. When used properly, social media can be an extremely 
efficient and effective communication method that provides benefits for both 
consumers and producers alike.
9
 However, the informality of a message 
communicated though this medium creates an inherent risk of deception. 
For example, a drug manufacturer was recently issued a formal warning 
letter by the FDA for a deceptive ad posted by social media maven Kim 
Kardashian.
10
 With more than forty-eight million followers,
11
 Kardashian is 
one of the most followed people on Instagram and is often paid by companies 
to endorse products.
12
 The Instagram post at issue was a picture of Kardashian 
holding a bottle of the morning sickness medication, Diclegis, while making 
one of her signature selfie faces.
13
 The caption attached to the filtered photo 
was a glowing review about the positive effects of the drug, and a claim that 
 
 7 Social Media: Consumer Compliance Risk Management Guidance, FDIC FIL-56-13 (2013), 2013 WL 
6515995 at pt. II. 
 8 Id. 
 9 See Jason DeMers, The Top 10 Benefits of Social Media Marketing, FORBES (Aug. 11, 2014, 12:24 
PM), http://www.forbes.com/sites/jaysondemers/2014/08/11/the-top-10-benefits-of-social-media-marketing/. 
 10 Thomas M. Burton, FDA Sends Warning Letter After Kim Kardashian Touts Morning Sickness Drug, 
WALL ST. J (Aug. 12, 2015), http://www.wsj.com/articles/fda-sends-warning-letter-after-kim-kardashian-touts-
morning-sickness-drug-1439401985.  
 11 Kim Kardashian (@kimkardashian), INSTAGRAM, https://instagram.com/kimkardashian/ (last visited 
Oct. 18, 2015). 
 12 See Caitlin O’Toole, Kim Kardashian: The Queen of Endorsements, WETPAINT (Dec. 7, 2011), 
http://www.wetpaint.com/kim-kardashian-the-queen-of-endorsements-698802/.  
 13 Ashlee Kieler, After FDA Warning, Kim Kardashian Posts Corrected Endorsement of Morning 
Sickness Pill, CONSUMERIST (Aug. 31, 2015), http://consumerist.com/2015/08/31/after-fda-warning-kim-
kardashian-posts-corrected-endorsement-of-morning-sickness-pill/.  
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“there was no increased risk to the baby” when taking the morning sickness 
medication.
14
 In its formal warning letter to the drug’s manufacturer, 
Duchesnay USA, the FDA stated the endorsement was deceptive because it 
failed to communicate any risk information. This is especially problematic on a 
public policy level because it “suggest[s] that Diclegis is safer than has been 
demonstrated.”
15
 In response to the FDA’s warning, Kardashian deleted the 
original post and replaced it with the following caption: 
#CorrectiveAd I guess you saw the attention my last 
#morningsickness post received. The FDA has told Duchesnay, Inc., 
that my last post about Diclegis (doxylamine succinate and 
pyridoxine HCl) was incomplete because it did not include any risk 
information or important limitations of use for Diclegis. A link to this 
information accompanied the post, but this didn’t meet FDA 




The post went on to list important safety information such as allergy 
concerns, common side effects, and a link to a website created by Duchesnay 
USA with more information about the drug.
17
 The new caption was in 
compliance with the FDA’s standards, but far exceeded the typical length of an 
Instagram post, which for some is nothing more than a few expressive emojis. 
The risk of deception through social media advertising can be even greater 
when using a social media platform that has a character limitation requirement. 
B. Character Limited Platforms (CLP’s) 
As demonstrated in the introductory examples, CLP’s are creating 
problems in the world of advertising. While many of the examples in the 
guides and in this Article involve Twitter, CLP’s are not limited to Twitter. 
CLP’s are found on any website that allows users to communicate a message 
but limits that communication in some way or another.
18
 This limitation may 
be on how many words a user is allowed to write or how many photos that they 
 
 14 See Burton, supra note 10. 
 15 Daina B. Solomon, FDA Issues Warning over Kim Kardashian’s Drug Promotions, L.A. TIMES 
(Aug.  11, 2015), http://www.latimes.com/business/la-fi-fda-kardashian-20150811-story.html.  
 16 Josh Wolford, Kim Kardashian Forced to Post a ‘Corrective Ad’ After FDA Called Previous One 
Misleading, WEBPRONEWS (Aug. 31, 2015), http://www.webpronews.com/kim-kardashian-forced-to-post-a-
corrective-ad-after-fda-called-previous-one-misleading-2015-08/.  
 17 Id. 
 18 See generally Charlene Kingston, How to Use Twitter for Business and Marketing, SOC. MEDIA 
EXAM’R (Apr. 10, 2013), http://www.socialmediaexaminer.com/how-to-use-twitter-for-business-and-
marketing/.  
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are allowed to post. The limitation could be one word or ten thousand words. 
Accordingly, any platform that does not allow you to fully communicate your 
message is considered a CLP for the purposes of this Article. So while many of 
the examples are based on Twitter, the guidance of the agencies can be 
applicable to any CLP that limits one’s ability to fully communicate their 
message. 
II. BRIEF OVERVIEW ON FEDERAL AGENCIES CREATED TO PROTECT THE 
CONSUMER 
A. Agencies in General 
Administrative agencies are created by Congress or the President to carry 
out governmental programs.
19
 While there are many different sources that 
regulate and govern the activities of administrative agencies, understanding the 
concept of an enabling statute will be sufficient for the purpose of this Article. 
An enabling statute specifically empowers an agency to take certain actions 
and generally an agency may not act beyond its permissive scope.
20
 These 
enabling statutes typically require the agency to assist the government in the 
regulation of a specific industry by gathering data, granting licenses, creating 
policy, as well as enforcing and adjudicating disputes.
21
 When confusion is 
voiced over how a regulation should be applied in a specific circumstance, the 
agencies will typically publish guidance (“guides”) on how an entity should 
proceed.
22
 While these guides are not legally binding, they are representations 





 19 See U.S. Const. art. I, § 1; Administrative Agencies, US LEGAL, http://system.uslegal.com/ 
administrative-agencies/ (last visited Oct. 25 2015); A Note on Administrative Agencies, THE HERITAGE GUIDE 
TO THE CONSTITUTION, http://www.heritage.org/constitution/articles/2/essays/101/a-note-on-administrative-
agencies (last visited Oct. 25 2015). 
 20 See Administrative Law And Procedure, THEFREEDICTIONARY, http://legal-dictionary. 
thefreedictionary.com/Administrative+Law+and+Procedure (last visited Oct. 25 2015); Administrative 
Agency, THEFREEDICTIONARY, http://legal-dictionary.thefreedictionary.com/Administrative+Agency.  
 21 See About Administrative Law, LOYOLA UNIV., http://lawlibguides.luc.edu/content.php?pid=128348 
&sid=1101470 (last visited Oct. 25, 2015); Administrative Agencies, supra note 19. 
 22 See Definitions of Guidance Documents, EPA, http://www2.epa.gov/laws-regulations/definitions-
guidance-documents (last visited Oct. 25, 2015). 
 23 See Jill E. Family, Easing the Guidance Document Dilemma Agency by Agency: Immigration Law and 
Not Really Binding Rules, 47 U. MICH. J.L. REFORM 1 (2013), available at http://repository.law.umich. 
edu/mjlr/vol47/iss1/1.  
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B. Guidance from the FDA and FTC 
1. The FDA 
The Federal Food, Drug and Cosmetic Act created the U.S. Food and Drug 
Administration (“FDA”) in an effort to manage the inherent risks associated 
with drugs and other medical devices.
24
 The FDA has been given very broad 
regulatory authority over products associated with food and drugs.
25
 This broad 




The FDA is currently in the process of publishing guides specifically 
addressing how an advertiser should proceed when utilizing a CLP.
27
 On June 
18, 2014, the FDA posted a draft guidance titled “Internet/Social Media 
Platforms with Character Space Limitations: Presenting Risk and Benefit 
Information for Prescription Drugs and Medical Devices.”
28
 The FDA is 
currently waiting for additional comments in order to publish an effective 
guidance article, and therefore the current draft contains nonbinding 
recommendations.
29
 However, regardless of the binding power of the draft, the 
FDA’s specific focus on CLP’s is beneficial to this analysis of advertising on 
CLP’s in general. While the FDA does not make its guides with the intention 
of providing guidance to industries outside of their authority,
30
 its analysis, tips 
and considerations help us fill in holes left by the FTC’s broad guidance. 
2. The FTC 
The Federal Trade Commission “FTC” was created on September 26, 1914, 
after President Woodrow Wilson signed the Federal Trade Commission Act 
 
 24 See 21 U.S.C. § 1705; What We Do, U.S. FOOD AND DRUG ADMIN., http://www.fda.gov/AboutFDA/ 
WhatWeDo/ (last visited Aug. 05, 2014). 
 25 What Does FDA Regulate?, U.S. FOOD AND DRUG ADMIN., http://www.fda.gov/AboutFDA/ 
Transparency/Basics/ucm194879.htm (last updated June 12, 2014). 
 26 Id. 
 27 See FDA Guides, supra note 5. 
 28 Id. 
 29 U.S. FOOD & DRUG ASS’N, INTERNET/SOCIAL MEDIA PLATFORMS WITH CHARACTER SPACE 
LIMITATIONS—PRESENTING RISK AND BENEFIT FOR PRESCRIPTION DRUGS AND MEDICAL DEVICES: DRAFT 
GUIDANCE FOR INDUSTRY (2014), http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory 
information/guidances/ucm401087.pdf.  
 30 U.S. FOOD & DRUG ASS’N, supra note 29, at 1. Page one of the FDA Guides specifically states that the 
guides were intended for manufacturers packers and distributors of prescription human and animal drugs and 
medical devices for human use. 
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(“FTCA”) into law.
31
 The stated mission of the FTC is to protect consumers 
and promote competition in the marketplace.
32
 The FTCA is the primary 
enabling statute of the FTC, and empowers the FTC with the authority to 
protect consumers from unfair or deceptive acts affecting commerce.
33
 It 
fulfills its stated purpose through regulation, enforcement, and establishing 
requirements that prevent deception.
34
 Since the creation of the FTC, the 
agency has developed policies and regulations aimed at protecting the 




While the FDA guidance is directed at the Food and Drug industry, the 
FTC’s focus is much broader and extends to the majority of transactions in the 
marketplace.
36
 The FTC has revised its guides on how an advertiser should 
advertise on a CLP.
37
 
The first half of this Article will focus on guidance from the FTC and FDA 
on how to portray a non-deceptive message on a CLP. The first guide that we 
will examine, “DOT COM Disclosures,” makes an effort to describe details 
that businesses should consider while developing advertisements for online 
media.
38
 While the FDA guides give a more detailed analysis of how a 
 
 31 Our History, FED. TRADE COMM’N (last visited Mar. 15, 2015), https://www.ftc.gov/about-ftc/our-
history.  
 32 What We Do, FED. TRADE COMM’N (last visited Mar. 15, 2015), http://www.ftc.gov/about-ftc/what-
we-do.  
 33 Federal Trade Commission Act, FED. TRADE COMM’N (last visited Mar. 15, 2015), https://www.ftc. 
gov/enforcement/statutes/federal-trade-commission-act. What We Do, supra note 32. 
 34 See Statutes Enforced or Administered by the Commission, FED. TRADE COMM’N (last visited Mar. 15, 
2015), http://www.ftc.gov/enforcement/statutes.  This is a very general summary of the authority given to the 
FTC by the FTCA enabling act. The FTC has published a more specific summary of its powers granted by the 
FTCA on their website. 
 35 Id.; see Rules, FED. TRADE COMM’N (last visited Mar. 15, 2015), http://www.ftc.gov/enforcement/ 
rules. Commission rules are published in Title 16 of the Code of Federal Regulations. The FTC has provided a 
link to the CFR on its website. Competition Advisory Opinions, FED. TRADE COMM’N (last visited Mar. 15, 
2015), https://www.ftc.gov/tips-advice/competition-guidance/competition-advisory-opinions. The website also 
provides links to other advisory opinions concerning proposed conduct. 
 36 See Competition Advisory Opinions, supra note 35; supra note 32. 
 37 The FTC’s Endorsement Guides: What People Are Asking, FED. TRADE COMM’N (last visited Mar. 15, 
2015), https://www.ftc.gov/tips-advice/business-center/guidance/ftcs-endorsement-guides-what-people-are-
asking.  
 38 See Press Release, Fed. Trade Comm’n, FTC Staff Revises Online Advertising Disclosure Guidelines: “Dot 
Com Disclosures” Guidance Updated to Address Current Online and Mobile Advertising Environment (Mar. 
12, 2013), https://www.ftc.gov/news-events/press-releases/2013/03/ftc-staff-revises-online-advertising-
disclosure-guidelines [hereinafter Dot Com Disclosures]. 
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marketer should proceed to advertise on a CLP, the FTC guides also address 
some of the issues that arise with space-constrained screens. 
The second half of this Article addresses the type of disclosure required by 
third party endorsements on a CLP. As we will see, an endorser can be an 
employee of the company making the product or a celebrity who has 
contracted to promote the product. It could prove to be problematic when an 
employee or celebrity endorser conveys a message on a CLP without 
disclosing the contractual relationship they have with the product’s company.
39
 
The advertiser could be held liable regardless of whether it had any control 
over the message.
40
 While to this date there has been no guidance published 
specifically addressing the issue of how much disclosure is required from an 
endorser on a CLP, the FTC has revised previous guides regarding 
endorsements and has added illustrative examples that include advertising on 
social media.
41
 While the publication of these revisions acted as a declaration 
that advertisements conveyed on CLP’s such as Twitter are not exempt from 
disclosure requirements, the revisions did very little to address the issue of 
when an endorser could be held liable.
42
 The second part of this Article will 
also provide examples and analysis on what is considered an endorsement, 
when liability is created, who is liable and when disclosure is required. 
III. FTC AND FDA GUIDANCE ON USING A CLP 
A. Messages Requiring Disclosures 
When deciding what amount of disclosure would be sufficient for any 
given message conveyed, an advertiser must first evaluate the language of the 
message and decipher whether there is a hidden claim or representation being 
communicated; this can be difficult.
43
 Sometimes an advertiser or endorser’s 
loyalty and admiration of the product can lead to an innocent representation 
that is actually deceptive in the eyes of a consumer. For example, the FDA 
provides an illustration in its guides of a seemingly innocent tweet that is 
 
 39 Id. 
 40 See 16 C.F.R. § 255.1 (2015). 
 41 See id. §§ 255.0-255.5. 
 42 See id. §§ 255.0-255.2, 255.5. 
 43 See FDA Guides, supra note 5. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory 
information/guidances/ucm401087.pdf.  
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actually a claim in disguise.
44
 This example involves a fictional drug called 
“No Focus” that was created for the purpose of battling mild to moderate 
memory loss.
45
 The firm promoting the product tweets, “No Focus for mild to 
moderate memory loss.”
46
 At first glance, the tweet seems to be an innocent 
representation of the drug and its purpose. However, as we will later see, the 
FDA would categorize this message as providing “benefit information” and 
states that such a message should be followed by sufficient risk information to 
avoid consumer deception.
47
 While similar statements might require less 
disclosure outside of the realm of prescription drug and FDA authority,
48
 this 
example illustrates the significance of examining each message thoroughly in 
order to find hidden claims or representations that require disclosure to prevent 
liability. 
B. Messages Not Requiring Disclosures 
It bears repeating that the sole purpose of providing a disclosure is to avoid 
deceiving the consumer. The FTC makes it clear that in order to decide 
whether some form of disclosure is required, the advertiser should view the 
message through the eyes of a reasonable consumer.
49
 Not all messages pose 
the inherent risk of consumer deception, and accordingly may require little 
disclosure, or in some cases, none at all.
50
 The FDA notes that mere 
“reminder” promotions are exempt from many of the labeling and advertising 
disclosure requirements.
51
 This would suggest that little to no disclosure would 
be required if a message can be categorized as a reminder promotion. The FDA 
describes a “reminder promotion” as a message that calls attention to the name 
of the product but does not make any representations or suggestions about the 
 
 44 See U.S. FOOD & DRUG ADMIN., supra note 29. At this point of the Article I am using the FDA’s 
example to illustrate the importance of language used on a CLP. The FDA is using this example in its guides to 
illustrate how little space is left for disclosing required risk information after using 40 out of the 140 character 
maximum for the benefit claim “No focus for mild to moderate memory loss”. 
 45 Id. 
 46 Id. 
 47 Id. 
 48 As discussed throughout the Article, there are more express disclosure requirements required by the 
FDA for products under its regulation due to the risks associated; i.e. if representation about firm’s 
prescription drug MUST include certain risk information. See 21 C.F.R. § 202.1(n) (2015), “brief statement of 
intended uses” and relevant risk information in restricted-device advertising. See id. § 202.1(r) (2015). 
 49 Dot Com Disclosures, supra note 38. 
 50 The FTC notes that under some circumstances, when utilizing a space-constrained advertisement, it 
might be acceptable to make the disclosures on a page to which the ad linked. Id. at ii, 10. 
 51 The FDA is not saying that Disclosure is never required for a “reminder promotion” just that they are 
exempt from many of the labeling and advertising disclosure requirements. FDA Guides, supra note 5. 
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product.
52
 Returning to the FDA’s example regarding “No Focus”, disclosure 
may not be necessary if it simply stated: “Ask your doctor about No Focus.”
53
 
According to this interpretation of the FDA’s guidance, this tweet would be an 
example of a reminder promotion; the firm makes no representations or 
misleading claims about the drug. These types of messages do not carry a risk 
of deception; they fail to make a representation about their product, and are 
only an effective marketing tool after the benefits and risks associated with the 
drug are common knowledge and understood by the consumer.
54
 
C. Adequate Disclosures 
Once an advertiser decides that the message it would like to portray 
requires some form of disclosure to avoid misconception, it should ensure that 
the disclosure is adequate.
55
 The guides provide similar instruction on how an 
entity should proceed in ensuring that its disclosure is sufficient to prevent 
consumer deception.
56
 While the guides focus on different aspects of an 
adequate disclosure,
57
 the general themes and analysis required are very 
similar. In deciding whether a disclosure is sufficient, an entity should always 
ask itself: (i) how much disclosure is needed with my product or service, (ii) 
does the benefit information balance with the risk information on my 
advertisement
58
, and (iii) is the disclosure being communicated effectively to 
the consumer? 
1. FTC Guidance on an Adequate Disclosure 
While the FDA is focused on ensuring that certain legally required 
disclosures are communicated effectively to the consumer, the FTC is more 
 
 52 Reminder Ad, U.S. FOOD AND DRUG ADMIN., http://www.fda.gov/Drugs/ResourcesForYou/ 
Consumers/PrescriptionDrugAdvertising/ucm083573.htm (last visited Mar. 30, 2015) (defining a reminder 
advertisement and providing examples). 
 53 FDA Guidance for Industry, supra note 44. 
 54 See Reminder Ad, supra note 52. 
 55 U.S. FOOD & DRUG ADMIN., supra note 29. 
 56 Id. 
 57 See U.S. DEP’T OF HEALTH AND HUMAN SERVICES, FOOD AND DRUG ADMIN., BRIEF SUMMARY AND 
ADEQUATE DIRECTIONS FOR USE: DISCLOSING RISK INFORMATION IN CONSUMER-DIRECTED PRINT 
ADVERTISEMENTS AND PROMOTIONAL LABELING FOR PRESCRIPTION DRUGS (2015); see also Dot Com 
Disclosures, supra note 38 (The FDA is able to focus more on how an advertiser should balance disclosures on 
a character-limited platform because many of the products that the FDA regulates require certain disclosures 
by law. The FTC, on the other hand, does not assume a disclosure is needed and is more concerned with how 
the message deceives the consumer). 
 58 FDA Guides, supra note 5, at 4 (The FDA goes into detail on this balancing test while reviewing an 
advertisement on a CLP). 
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concerned with the overall risk of deception in the advertisement.
59
 Disclosures 





 The FTC requires that the disclosures satisfy the 
“Clear and Conspicuous” requirement.
62
 It acknowledges that there is no bright 
line rule for determining whether a disclosure is clear and conspicuous, but 
provides a number of factors that an advertiser should focus on to avoid a 
violation.
63
 While many of the factors may have some effect on how an 
advertiser should proceed to advertise on social media CLP’s, this Article is 
concentrated on the actual message being portrayed on a CLP such as Twitter. 
For the purpose of the first half of this Article, assume that a company is 
analyzing how it should articulate the language of an advertisement on Twitter 
to avoid deception. Also assume that whatever message the entity conveys will 
be easily read on the device being used to view it, and any disclosures within 
the message are placed near the ad in a non-conspicuous way. 
2. Necessary Disclosures 
A popular belief in the world of CLP advertising is that a simple hyperlink 
or #AD at the end of an advertisement will effectively prevent an 
advertisement from being deemed deceptive.
64
 The guides are clear that 
standing alone, these abbreviated disclosures are insufficient in many 
situations.
65
 Often an advertisement must include necessary disclosures within 
 
 59 Id. at 3-5; FED. TRADE COMM’N, THE FTC’S ENDORSEMENT GUIDES: WHAT PEOPLE ARE ASKING 
(2013). 
 60 FED. TRADE COMM’N, FTC POLICY STATEMENT ON DECEPTION (Oct. 14, 1983) (The FTC’s deception 
policy describes an ad as deceptive if it contains a statement or omits information that is likely to mislead 
consumers acting reasonable under the circumstances and is “material” or important to a consumer’s decision 
to buy or use the product.). 
 61 See Dot Com Disclosures , supra note 38, at 5-6. 
 62 Id. at 6. 
 63 Dot Com Disclosures, supra note 38 at 7 (i. “[t]he placement of the disclosure in the advertisement and 
its proximity to the claim it is qualifying”; ii. “[t]he prominence of the disclosure”; iii. “[w]hether the 
disclosure is unavoidable”; iv. “[t]he extent to which items in other parts of the advertisement might distract 
attention”; v. “[w]hether the disclosure needs to be repeated several times in order to be effectively 
communicated, or because consumers may enter the site at different locations or travel through the site on 
paths that cause them to miss the disclosure”; vi. “[w]hether disclosures in audio messages are presented in an 
adequate volume and cadence and visual disclosures appear for a sufficient duration”; and vii. “[w]hether the 
language of the disclosure is understandable to the intended audience”). 
 64 See Benjamin Stein, FTC Updates FAQs on its Endorsement Guides, INFORMATION LAW GROUP 
(Oct. 21, 2015), http://www.infolawgroup.com/2015/06/articles/ftc/ftc-updates-faqs-on-its-endorsement-
guides/; Ann Tran, When To Use #Ad in Your Tweets, ANN TRAN (Oct. 19, 2015), http://ann-tran.com/2014/ 
04/when-to-use-ad-in-your-tweets/.  
 65 See Dot Com Disclosures, supra note 38, at 10. 
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the message to avoid consumer deception.
66
 An advertiser must decide if the 
disclosure would materially affect a consumer’s decision to purchase a product 
or service.
67
 If so, this disclosure needs to be placed in the advertisement itself 
rather than within a hyperlink.
68
 If an advertiser is unable to fit the disclosure 
and the intended message on the CLP, the entity should not use that platform.
69
 
Accordingly, identifying necessary disclosures is one of the most important 
preliminary determinations that an advertiser must make when deciding 
whether or not to advertise on a CLP.
70
 
An advertiser that creates products as opposed to providing services might 
need a disclosure for several reasons. These reasons include warranties 
communicated in the message, statements of a product’s condition, and risks 
associated with the product.
71
 The simplest illustration of a “necessary 
disclosure” is prescription drugs. The FDA guides note that, at a minimum, the 
firm’s message should include the most serious risks associated with the drug 
or medical device.
72
 The FDA describes a serious risk as one that would 
include all risks known to be fatal or life threatening, even if they are also 
represented on the box of the product.
73
 It further states that even if a drug does 
not have a boxed warning, fatal risks, or contradictions, the most significant 
warnings or precautions about the product should still be communicated in the 
message.
74
 This suggests that even products with low inherent risks are 
required to provide some type of disclosure in the message itself, outside of the 
hyperlink. 
Unlike advertisements for products such as pharmaceutical drugs, 
advertisements for services are less likely to pose risks for physical injury to 
 
 66 Id. 
 67 Fed. Deposit. Ins. Corp., FIL-26-2004, Unfair or Deceptive Acts or Practices by State-Chartered 
Banks, FDIC (Mar. 11, 2004), available at https://www.fdic.gov/news/news/financial/2004/fil2604.html.  
 68 Dot Com Disclosures, supra note 38, at 10. 
 69 Id. at 6–7. 
 70 FTC- in determining whether the disclosure should be placed in the space-constrained ad itself or on 
the website to which the ad links, advertisers should consider how important the information is to prevent 
deception, how much information needs to be disclosed, the burden of disclosing it in the ad itself, how much 
information the consumer may absorb from the ad, and how effective the disclosure would be if it were made 
on the website”. Id. at pt. III C(1)(e). “Evaluating Proximity in Space-Constrained Ads.” Id. at 6. 
 71 Id. at 10. 
 72 FED. DRUG AGENCY, GUIDANCE FOR INDUSTRY INTERNET/SOCIAL MEDIA PLATFORMS WITH 
CHARACTER SPACE LIMITATIONS—PRESENTING RISK AND BENEFIT INFORMATION FOR PRESCRIPTION DRUGS 
AND MEDICAL DEVICES 9 (June 2014), http://www.fda.gov/downloads/drugs/guidancecomplianceregulatory 
information/guidances/ucm401087.pdf.  
 73 FDA Guides, supra note 27, at 9. 
 74 Id. 
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consumers. Accordingly, advertisers of services should focus on the risk of the 
potential for deception in the statement. For example, many services have 
hidden fees material to a consumer’s decision to purchase the services.
75
 If any 
fees would be deemed a necessary disclosure, it must be included in the 
message to avoid liability.
76
 
D. Utilizing the Hyperlink 
A hyperlink is a valuable tool for an entity utilizing a CLP.
77
 A hyperlink is 
a link included in the message that allows an interested consumer to be 
directed to a separate page that might include the product website or a page of 
disclosures. A hyperlink can be in the form of a specific message or a short 
sequence of letters that are generally known to be a hyperlink.
78
 While there is 
no exact test to determine the extent of disclosure necessary to prevent a 
message from being deemed deceiving,
79
 the guides suggest to provide at least 
some type of disclosure in the message itself and the remaining material 
information in a separate page accessed through a hyperlink.
80
 Regardless of 
form, the hyperlink must be easily recognizable by the consumer or it will fail 
to prevent the deception intended by its placement.
81
 However, while a 
hyperlink can be a valuable tool in providing non-necessary disclosures, it also 





 75 Supra note 70 at 10.  
 76 Id. at A-4, A-15. 
 77 Dot Com Disclosures, supra note 38, at 10 (stating that “hyperlinks can provide a useful means to 
access disclosures that are not integral to the triggering claim”). 
 78 Id. at 11; Anjali Dalal, Protecting Hyperlinks and Preserving First Amendment Values on the Internet, 
13 U. PA. J. CONST. L. 1017, 1018–19 (2011); Manny D. Pokotilow et al., Internet Linking and Framing Issues, 
SM045 ALI-ABA 37, 39 (2007). 
 79 DOT COM DISCLOSURES, supra note 38, at 7 (stating “there is no set formula for clear and 
conspicuous disclosures” and that “it depends on the nature and form of the advertisement.” In evaluating “the 
clear and conspicuous requirement,” the FTC provides a list of factors to consider including “the placement of 
the disclosure in the advertisement” and “whether the language of the disclosure is understandable to the 
intended audience”). 
 80 Id. at 10 (stating “disclosures that are an integral or inseparable part of a claim should not be 
communicated through a hyperlink” but rather “should be placed . . . immediately next to the claim”); Id. at 8, 
10; FDA Guides, supra note 27, at 10. 
 81 Dot Com Disclosures, supra note 38, at 11. 
 82 See id. at 10–11 (stating information that should not be disclosed via hyperlink includes cost 
information, health and safety disclosures or other hidden fees that a consumer would not expect to incur). 
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E. The Final Determination 
While the FDA and FTC guides have helped clarify questions on strategy, 
there is still much confusion on how much disclosure is required by an 
advertiser utilizing a CLP.
83
 However, one message is clear. If an advertiser 
cannot articulate a message on a CLP that is both effective and fulfills the 
disclosure requirements, it should not use that platform.
84
 If an advertiser does 
use a CLP to advertise, it should ensure that it has a detailed risk-management 




F. Effective Risk Management Systems 
While many industries are not required to have a risk management system 
(“RMS”) in place, it is strongly recommended by the guides.
86
 The guides 
suggest that the amount of detail required in the RMS should be proportionate 
to the amount of marketing that the advertiser would like to use on a CLP.
87
 
Advertisements for products or services associated with a higher risk of 
physical or financial harm should include more detailed monitoring systems 
than advertisements for products with low risks of harm to the consumer.
88
 
Advertisers that choose to market frequently on a CLP should have more 
detailed monitoring systems than advertisers that use other marketing 
methods.
89
 Thus, there is no perfect test to determine how much detail or 
resources that an advertiser should direct towards its risk management 
program. 
A critical problem with inadequate monitoring systems can arise from the 
use of a CLP by a third party associated with the entity.
90
 Should endorsements 
 
 83 See id. at 6–7. 
 84 FDA Guides, supra note 27, at 5; see Dot Com Disclosures, supra note 38, at 6–7 (stating “if 
disclosure is necessary to prevent an advertisement from being deceptive, unfair or otherwise … and it is not 
possible to make the disclosure clearly and conspicuously” then either the claim should be modified or the “ad 
should not be disseminated.” Moreover, “if a particular platform does not provide an opportunity to make clear 
and conspicuous disclosures . . . it should not be used to disseminate advertisements that require such 
disclosures”). 
 85 Fed. Deposit Ins. Corp., FIL-56-2013, Social Media: Consumer Compliance Risk Management 
Guidance, FDIC (Dec. 11, 2013), available at https://www.fdic.gov/news/news/financial/2013/fil13056.pdf. 
 86 Social Media: Consumer Compliance Risk Management Guidance, 78 Fed. Reg. 4,848, 4,850 (Jan. 23, 
2013), available at http://www.occ.treas.gov/news-issuances/federal-register/78fr4848.pdf.  
 87 Id. 
 88 Id. 
 89 Id. 
 90 Advertising Guides, supra note 2 at 53,124. 
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of a product or service on a CLP be analyzed the same way as if the entity had 
communicated the message itself? In other words, should an endorsement by a 
third party subject to a contractual relationship with an entity be subject to the 
disclosure requirements above? 
IV. DISCLOSURES AND THIRD PARTY ENDORSEMENTS 
A. Additional Disclosure Requirements for Third Parties 
While the guides can be useful in directing an advertiser in marketing its 
own product using a CLP, they lack guidance about how disclosures should be 
handled by a third party that is being compensated to endorse a product or 
service via CLP.
91
 It would seem contrary to public policy to allow an 
advertiser to circumvent the disclosure requirements discussed in the first half 
of this Article by paying a celebrity or other third party to endorse its product. 
In fact, it would seem that there is an even greater risk of deception when a 
third party is promoting a product without revealing that they are benefiting 
from their message.
92
 As discussed above, the increased risk of deception to 
consumers requires a greater need for additional disclosure. 
B. FTC Guides on Endorsements 
In response to the inherent deception that is created with endorsements of 
products and services on new media, the FTC revised its guides to include 
several examples of how they apply to new forms of consumer-generated 
media. These revisions were created to provide a basis for advertisers and 
endorsers to comply with the FTC’s provisions and did not purport to cover 
every possible use of an endorsement in an advertisement.
93
 These new 
additions were immediately met with criticism; many commenters argued that 
it was premature to apply these guides to new media without further discussion 
about the scope of liability this would create for advertisers.
94
 Other 
commenters argued that the effect of these revisions would deter advertisers 
 
 91 FDA Guidance Limits Flexibility in Social Media Promotional Communications, SKADDEN, ARPS, 
SLATE, MEAGHER & FLOM L.L.P. (July 21, 2014), https://www.skadden.com/insights/fda-guidance-limits-
flexibility-in-social-media-promotional-communications (last visited Oct. 23, 2015). 
 92 Guides Concerning the Use of Endorsements and Testimonials in Advertising, supra note 90 at 
53,127. 
 93 Id. at 53,138. 
 94 Id. at 53,125. 
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from using these forums and stunt its growth.
95
 Nonetheless, the revisions were 
added. 
While the revisions helped entities understand that third party endorsers can 
create liability for the entity or third party through a CLP advertisement, there 
are still many questions regarding the amount of disclosure needed by an 
endorser and when the endorsers themselves are shielded from liability.
96
 
1. What Is an Endorsement and Who Is an Endorser? 
The FTC defines an endorsement as any advertising message or statement 
that consumers are likely to believe reflects the opinions, beliefs, or 
experiences of a party other than the sponsoring advertiser.
97
 The guides also 
state that it is irrelevant if the message contained in the endorsement is 
identical to the views of the advertiser.
98
 Therefore, the focus is on the 
consumer’s perception of the endorsement, rather than the endorser’s 
intentions. Commenters argue that focusing on consumer perception in the 
realm of endorsements creates inherent uncertainty.
99
 However, the FTC 
dispels that argument by reiterating that the focus on the consumer’s takeaway 




To determine what constitutes an endorsement and who can be classified as 
an endorser, the FTC makes the analysis through the eyes of a reasonable 
consumer.
101
 The FTC states that not every person who espouses a beneficial 
message about a product or service will be considered an endorser.
102
 A 
statement made by an announcer “who is not familiar to consumers” may not 
be an endorsement, unless that announcer is a spokesperson for the advertising 
 
 95 Id. 
 96 See id. at 53,128 (Stating many commenters criticized the FTC for the lack of guidance of when an 
endorser would be liable. They argued it would require “celebrities to educate themselves” on the product, 
industry and competition and expose them to liability for claims beyond their expertise or control. They also 
argued that the risk of liability would deter them from endorsing products and create a chilling effect. The FTC 
claims the new examples featuring celebrities do not create new liability for celebrities but instead serves to 
warn them and their advisors about the potential liability associated with their endorsement activities). 
 97 Id.at 53,124. 
 98 Id. 
 99 Id. at 53,124-25. 
 100 Id. at 53,125. 
 101 Id. 
 102 Id. at 53,125-26. 
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company and is speaking on its behalf.
103
 However, a “well-recognized” 
professional golfer driving a particular brand of golf balls off a tee during a 
television commercial would be considered an endorser.
104
 Other examples 
illustrating endorsements suggest that once an individual achieves a level of 
recognition, their statements become more susceptible to being characterized 
as an endorsement by the FTC.
105
 However, the FTC has not deemed every use 
of social media to discuss a product as an endorsement.  
This Article focuses on two types of individuals that would qualify as 
endorsers in my interpretation of the guides. The first type of endorser would 
be an individual who is highly recognized by the public and has sufficient 
influence on consumers (“celebrity endorsers”). Celebrity endorsers include 
actors, singers, public figures, politicians, and professional athletes. The 
second type of endorser would be any individual who is not well known by the 
public, but has a beneficiary relationship with the success of the product or 
services (“beneficiary endorsers”). Beneficiary endorsers include high-ranked 
employees in a company, or a single individual, who benefit from the product 
sales. 
a. Disclosing a Material Connection 
The FTC requires disclosure of “Material Connections” between an 
advertiser and endorser inside each advertisement to prevent consumer 
deception.
106
 This suggests that not every connection between the advertiser 
and endorser needs a required disclosure. In order for disclosure to be required, 
the connection must be material. It defines a material connection as one that 
exists between the endorser and the seller of the advertised product that might 
materially affect the credibility of the endorsement.
107
 Technically, a low-
ranked employee of a business would fit this definition, and the FTC has 
included an example of employees that create liability via online posts.
108
 This 
Article will focus on endorsers who directly benefit from the commission of 
sales of a product rather than employees who are working for an hourly wage. 
 
 103 Id. at 53,138. 
 104 Id. 
 105 Id. (e.g., “ an announcer who is not familiar to consumers”, “a well-known professional automobile 
racing driver”, “a prominent and well-recognized professional golfer”, “well-known entertainer”, “well-known 
female comedian”, “well-known celebrity”, “well-known professional tennis player” “who is neither known to 
the public”). 
 106 16 C.F.R. § 255.5. 
 107 Id. 
 108 Id. at example 8. 
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b. Additional Disclosure Requirements for Third-Party Endorsements 
Section 255.1 of the FTC’s revised guide on endorsements provides 
advertisers and endorsers with general considerations for promoting 
products.
109
 Below are two that have generated a lot of criticism, but are useful 
in our analysis of the disclosure requirements on a CLP: 
(a) “Endorsements must reflect the honest opinions, findings, beliefs, or 
experience of the endorser. Furthermore, an endorsement may not convey any 




(d) “Advertisers are subject to liability for false or unsubstantiated statements 
made through endorsements, or for failing to disclose material connections 
between themselves and their endorsers. Endorsers also may be liable for 
statements made in the course of their endorsements.”
111
 
First, the guide makes it clear that an advertisement conveyed by an endorser is 
not exempt from the disclosure requirements discussed above.
112
 Consideration 
(a) states that an endorsement cannot state an express or implied representation 
that would be deceptive if made directly by the advertiser.
113
 Consideration (d) 
uses the false and unsubstantiated language that we discussed in the first half 
of this Article.
114
 Accordingly, if an endorser decides to make a statement 
about a product on a CLP, he or she must also ensure that the message is not 
deceptive or misleading.
115
 But as discussed earlier, an endorsement that is not 
representative of what consumers can generally expect to achieve with the 
product or service is a deceptive endorsement. In many cases, an opinion or a 
testimony of a product would fit this definition.  
For example, assume a celebrity that has contracted to promote a brand of 
acne medication labeled “ACNE-GONE” tweeted out the following message: 
“Acne-gone cleared my acne in 2 days #bumpsbegone #AD” 
 
 109 16 C.F.R. § 255.1 
 110 Advertising Guides, supra note 2, at § 255.1 (2011). 
 111 Id.  
 112 16 C.F.R. § 255.1. 
 113 Id. 
 114 Id.  
 115 Id. 
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While this is a clear representation of an endorser’s experience with a product, 
which is protected under consideration (a), it may still be considered deceptive 
if that was not the performance consumers would generally expect to achieve 
with the product.
116
 Accordingly, this statement requires additional disclosure 
from the advertiser to avoid deception.
117
 
Advertisers and endorsers can both be subject to liability for misleading 
advertisements.
118
 Thus, advertisers should have some type of regulatory 
system in place to avoid liability stemming from third-party statements on a 
CLP.
119
 Companies have expressed concern about being subject to liability for 
an endorser’s message, which they did not write.
120
 They argue that they 
should only be liable if they had control over the advertisement.
121
 The 
Commission’s response is that regardless of control, the company initiated the 
process that led to the endorsement and should not be shielded from liability 
for misleading statements made by endorsers.
122
 
Returning to the example of “Acne-gone,” assume the celebrity was found 
to have communicated a deceptive message via Twitter. Under consideration 
(a), the celebrity would have a strong defense against being found liable based 
on the argument that his or her statement was a truthful reflection of his or her 
experience with the product.
123
 However, while the third-party endorser may 
avoid liability from the statement, it does not mean that the advertiser of the 
product will also avoid liability.
124
 The focus is on the injury sustained by the 
 
 116 Id. 
 117 Id. 
 118 Id. 
 119 Advertising Guides, supra note 2 (In its guides the FTC suggests that an employer’s effort to comply 
with regulation through institution of policies and practices concerning “social media participation” by its 
employees will be a factor in its decision to enforce its regulations in court. They also suggest that an 
enforcement action is not likely to be used in the case of a single “rogue” employee who violated established 
company policy that adequately covered the conduct in question.) 
 120 Id. at 53,134-35. 
 121 Id.  
 122 Id. at 53,135. 
 123 16 C.F.R. § 255.5. (Example 2 suggests that a celebrity endorser may avoid liability when only 
expressing truthful opinions and personal preferences about a product.) 
 124 Id. 
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consumer.
125
 The Shaggy Defense, “[i]t wasn’t me,”
126
 is not going to protect 
the advertiser in this situation.
127
 
The guides are not clear in regards to when an endorser will be held liable. 
The guides state that liability will be determined on a facts and circumstances 
basis.
128
 This Article will describe three different scenarios in which the 
endorser may be subject to liability for deceptive messages. All three scenarios 
focus on the objective intent of the endorser.  
First Scenario 
“An endorser should be held liable for failing to adequately disclose the 




The guides clearly suggest that not everybody who endorses a product will 
be considered an endorser.
130
 To be an endorser, one would have to achieve 





For liability to attach in scenario one, first look to the endorser’s intent. 
While there are exceptions to every rule, celebrity endorsers have gained a 
high level of influence through hard work and dedication. They are often 
conscious of the impact their statements have on their fans, and with influence 
comes responsibility. A reasonable person in their position should understand 
that advertising a product they are contracted to promote, without adequately 
disclosing it, is inherently deceptive to their fans or followers. This reasonable 




 125 See supra note 122 at 53,125. 
 126 See Josh Levin, The Shaggy Defense: America’s Favorite New Legal Term, SLATE (June 7, 2010, 
11:59 AM), http://www.slate.com/blogs/browbeat/2010/06/07/the_shaggy_defense_america_s_favorite_new_ 
legal_term.html.  
 127 See THE FTC’S ENDORSEMENT GUIDES: WHAT PEOPLE ARE ASKING, FED. TRADE COMM’N, available 
at https://www.ftc.gov/system/files/documents/plain-language/pdf-0205-endorsement-guides-faqs_0.pdf.  
 128 See Guides Concerning the Use of Endorsements and Testimonials in Advertising, 74 16 C.F.R. 
§ 255.0(a) (2015), available at http://www.ecfr.gov/cgi-bin/text-idx?SID=de10601c673ac6ac7500291db 
fecca38&mc=true&node=pt16.1.255&rgn=div5 . 
 129 See Id. § 255.1(c) (2015). 
 130 Advertising Guides, supra note 2 at 53,125–26. 
 131 Id. at 53,126. 
 132 Id. 
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Beneficiary Endorsers 
The same analysis used for celebrity endorsers can be applied to 
beneficiary endorsers. Under the objective standard, a reasonable person would 
understand that endorsing a product or service that he or she directly benefits 
from is deceptive to a consumer when not adequately disclosed. Online 
forums, product and service review sites, and online marketplaces have a large 




For example, David, the creator of the drug Acne-Gone, sold the product to 
a well-established business that would be able to produce and distribute it 
globally. He not only uses and loves his product, but also loves the 20% 
commission that he receives from its sales. Acne-Gone is a new product and 
many of the websites that sell this product have limited consumer reviews. In 
an effort to jump-start the product’s popularity, David skims the Internet 
review sites and anonymously posts the following message on each one: 
“This product is amazing. I will never buy another acne cream. I honestly have 
only used it a couple days and my face is clearer than it has ever been. I 
definitely recommend purchasing this product.” 
Regardless of whether David’s statement is true, the message is considered 
deceptive according to the guides of the FTC.
134
 This is a statement that does 
not represent the benefits that a consumer should expect with this product.
135
 
David’s intentions and anonymous status may support the argument that he 
was not making an advertisement.
136
 However, surely this message would fit 
the definition of an endorsement, and his material connection with the product 
would qualify him as an endorser.
137
 As stated above, an endorsement message 
cannot make a representation that would be deceptive if expressly stated by the 
advertiser.
138
 Therefore, the advertiser would be liable for this deceptive 
 
 133 See Chayap Katawetawarks & Cheng Lu Wang, Online Shopping Behavior: Influences of Online 
Shopping Decision, 1 ASIAN J. BUS. RES. 66, 67 (2011), available at http://www.magscholar.com/joomla/ 
images/docs/ajbr/ajbrv1n2/Online%20Shopper%20Behavior%20Influences.pdf.  
 134 See 16 C.F.R. § 255.5 (2015). 
 135 Id.  
 136 Advertising Guides, supra note 2. 
 137 Id. at 255.5.  
 138 Id. at 255.1.  
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statement,
139
 and David would be liable as an endorser for failing to disclose 
his material connection with the product.
140
 
Thus, after using an objective analysis of the endorser’s intent, we find that 
endorsers would also be liable for failing to disclose the material connection 
that they have with a product or service.
141
But what about in situations where 
they disclose their relationship? 
Second Scenario 
“An endorser should be held liable when the message communicated on the 




The guides suggest that an endorser can be found liable for making a 
deceptive statement about their personal experience with the product or 
service.
143
 An endorsement should reflect the honest opinions, findings, 




Matthew is a professional basketball player, and has an endorsement deal 
with a shoe company, “AIR-JOHNS.” Matthew’s Twitter followers are 
unaware that Matthew is an endorser of AIR-JOHNS’ shoes. Matthew is told 
by his agent that the first set of test results for the new AIR-JOHNS 3s show 
that the shoes instantly increased test participants’ vertical jump by three 
inches. Matthew was still waiting to receive his pair of AIR-JOHN 3s, when he 
posted the following tweet: 
The new Air-John 3s are in. Just increased my vertical by 3 inches. 
#Flying#AD 
Although Matthew has merely repeated results of the test and disclosed his 
material connection with the product by using the hashtag #AD, the message is 
clearly deceptive to the consumers regardless of his intentions.
145
 He has not 
personally experienced the shoes’ benefits, and the shoes have not increased 
 
 139 Id.  
 140 Id.  
 141 Id. at § 255.5.  
 142 Id. at § 255.1. 
 143 Id.  
 144 Id.  
 145 See id. at § 255.2.  
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his vertical by 3 inches. By allowing celebrity endorsers to communicate 
tweets such as this one, pursuant to contract, or on their own free will, 
consumer deception is possible.
146
 
In contrast, suppose Matthew had gained a lot of weight in the last few 
months and decided to work on losing weight by jumping up and down one 
hundred times a day with his new AIR-JOHNS 3s. As a result, he lost a 
substantial amount of weight and the public is begging to know how. A 
company that markets a weight loss drug, “SKINNY-MAN”, calls Matthew’s 
agent and asks to use a “before and after” picture of Matthew to promote its 
product. The company assures Matthew’s agent that it will not put any 
messages in the advertisement claiming that Matthew used the product. 
Matthew and his agent discuss and agree to allow them to use the pictures in its 
advertisement. The company then posts ads throughout Facebook and other 
social media sites with the following message: 
BUY SKINNY-MAN clinically proven to lose weight fast 
Directly under that statement are Matthew’s before and after pictures. 
While Matthew is not directly quoted in the advertisement, by agreeing to 
allow them to use his pictures he is implicitly endorsing their product. The 
deception is clear. Consumers will assume that Matthew used “SKINNY-
MAN” to lose weight and will buy the product. This implication would violate 
general consideration (a), which states that if an endorsement makes a 
representation about an experience with a product, then that experience must 
be truthful.
147
 Therefore, while Matthew did not actually use the product, but 
consented to the company using his photos, Matthew should be held liable for 




Switching the analysis from celebrity endorsers to beneficiary endorsers, 
the same result occurs. Allowing beneficiary endorsers to make false claims 





 146 Id. at § 255.0. 
 147 See id. 
 148 Id. at 255.2.  
 149 Id. 
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Sam works for AIR-JOHNS and sells AIR-JOHNS products on a 
commission basis. Sam goes on YouTube and finds videos that review the new 
AIR-JOHNS 3s and writes: 
The guy in the video is right. These bad boys helped me finally touch the rim. 
They look good too. If anyone wants to buy a pair, I’ll give you a 20% 
discount. Email me at Samtheman@gmail.com 
Sam has never used the shoes, but immediately receives emails from 
consumers to purchase AIR-JOHNS 3s. Under the FTC, Sam’s beneficiary 
status qualifies him as an endorser,
150
 and he therefore violated general 
consideration (a) by making a false representation about his experience with 
the product. While consumers are not buying this product based on Sam’s 
celebrity status, his deceptive marketing strategy has influenced consumers.
151
 
In both the scenarios discussed above, it would seem easy enough for the 
endorser to avoid liability by disclosing the connection between the product 
and the endorser by using the hashtag #AD. However, the guides do not 
specifically state that #AD is sufficient.
152
 In contrast, the guides suggest that 
the use of #AD is not sufficient, and in the context of a CLP, every letter is 
important.
153
 Thus, an additional disclosure is probably needed for an endorser 




An endorser should be held liable for failing to disclose other required 
disclosures that would make the message deceptive when a reasonable 
consumer would feel that disclosure was a “deal breaker.”
155
 
In terms of designating liability, should the endorser be liable for failing to 
disclose his connection with the product, any necessary disclosures, and any 
hyperlinks to other disclosures required by agencies such as the FTC and 
FDA? This is a lot of information for a platform with a character limitation of 
 
 150 Id. 
 151 Id. 
 152 The FTC’s Endorsement Guides: What People Are Asking, FED. TRADE COMM’N 12 (May 2015), 
https://www.ftc.gov/system/files/documents/plain-language/pdf-0205-endorsement-guides-faqs.pdf.  
 153 Id. 
 154 .Com Disclosures: How to Make Effective Disclosures in Digital Advertising, FED. TRADE COMM’N 7 
(Mar. 2013), https://www.ftc.gov/sites/default/files/attachments/press-releases/ftc-staff-revises-online-
advertising-disclosure-guidelines/130312dotcomdisclosures.pdf [hereinafter Effective Disclosures].  
 155 Advertising Guides, supra note 2. 
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140 words or less. As discussed above, the FTC and FDA suggest that 
disclosure requirements need to be in the message itself, rather than in a 
hyperlink, in order to avoid deception or the possibility that a consumer would 
categorize the non-disclosed items as “deal breakers.”
156
 
By the time these disclosures are typed out, there is little room left for the 
endorser to convey any message about the product itself. Requiring this 
amount of disclosure on a CLP prevents many endorsers from advertising on 
these platforms. Further, many endorsers fear the liability attached to 
publication of a deceptive statement.
157
  
Consumers may be ultimately injured as well. Consumers often mimic their 
role models, and place trust in the services or products used by endorsers. 
While it is the opinion of this Article that endorsers should not be held to the 
disclosure standards discussed in the FDA and FTC guides, there are still many 
situations where additional disclosures should be required in addition to 
disclosing a material connection. 
To establish the extent of disclosure required in a situation, an objective 
standard should be used.
158
 To do so, consider the standard of a reasonable 
consumer to determine if an additional disclosure is a “deal breaker.”
159
 Would 
knowing that additional information materially effect a consumer’s decision to 
buy a product or service? 
For example, Jake used to be an obese individual. However, he decided to 
change his lifestyle and eat three sandwiches a day from the same sandwich 
restaurant down the street from his apartment, “SANDWICH”. While each 
sandwich was healthier than what Jake had previously been eating, the 
sandwiches still contained a high caloric content. In addition to eating the 
sandwiches, he jogged for two hours a day and quickly lost a significant 
amount of weight. SANDWICH watched his weight loss transition and signed 
Jake as a promoter for SANDWICH. Jake subsequently became a popular 
public figure, and gained a substantial number of Twitter followers. In 
recognition of his achievement he decides to tweet: 
Luv all my supporters. Can’t believe I lost 300 lbs eating at SANDWICH. #AD 
 
 156 Effective Disclosures, supra note 161 at A-17. 
 157 Advertising Guides, supra note 2. 
 158 Id. 
 159 Id. 
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In this situation, Jake would not be liable for deceiving consumers under 
our first two scenarios. Jake disclosed the material connection between himself 
and the product with the hashtag #AD, and lost the weight through his personal 
experience of eating at SANDWICH. However, Jake may be liable for failure 
to disclose “deal-breakers” because the consumers are under the impression 
that SANDWICH is the only reason Jake lost weight. Under an objective 
analysis, a reasonable person would understand that jogging two hours a day 
also contributed to Jake’s weight loss and would understand that fact to be a 
necessary disclosure. Accordingly, in order to avoid the message from being 
designated as deceptive, Jake would have to disclose the “deal-breaker” in his 




The uncertainty created from these guides as they relate to the ever-
expanding world of social media is apparent. I agree with commenters who 
argue that making the endorsement guidance applicable to new online media 
was premature. Advertisers and endorsers alike need to know how they should 
approach advertising on a CLP, and the risk of consumer deception is higher 
than it has ever been in this age of social media. Therefore, acting quickly and 
competently is critical in future regulation and guidance.  
If there is insufficient regulation, there is a greater risk of consumer 
deception by advertisers on social media sites. However, there are many 
benefits to consumers and advertisers alike in the use of CLP’s to advertise 
products. If there is excessive regulation, there is a risk of advertisers 
abandoning CLP’s altogether, which would ultimately injure the consumer. 
While concentrating on protecting the consumer, we sometimes forget that the 
consumer also has an inherent duty of due diligence.  
Regardless of all the confusion surrounding the disclosure requirements 
required on a CLP, one thing is certain: marketers will continue to find new 
strategies and platforms to advertise their products on platforms that have not 
 
 160 See Advertising Guides, supra note 2 at § 255.2. (This scenario is largely based off of the newly added 
example 4 and the FTC’s guidance-example 4 illustrates an example of a formerly obese woman claiming in 
an advertisement the following statement: “Every day, I drank 2 WeightAway shakes, ate only raw vegetables 
and exercised vigorously for six hours at the gym. By the end of six months, I had gone from 250 pounds to 
140 pounds.” In its guidance the FTC states that this statement would not be deceiving because she disclosed 
her exceptional circumstances under which she achieved her results. However, the FTC states that if she had 
merely posted “I lost 110 pounds in six months using WeightAway together with diet and exercise”, this 
description would not adequately alert consumers to the remarkable circumstances leading to her weight loss.) 
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been specifically addressed by the guides. Therefore, we should come up with 
a flexible standard that adapts with our ever-progressing online presence that 
continues to educate consumers to use their best judgment regarding product 
endorsements.  
 
